Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)
Latest Information Update: 03 Feb 2023
Price :
$35 *
At a glance
- Drugs Eltrombopag (Primary)
- Indications Chronic myeloid leukaemia; Myelofibrosis; Thrombocytopenia
- Focus Therapeutic Use
- 04 Jan 2022 Status changed from active, no longer recruiting to completed.
- 04 Jan 2022 Planned primary completion date changed from 31 Jan 2021 to 31 Jan 2022.
- 29 Jul 2020 Planned End Date changed from 31 Jan 2020 to 31 Jan 2022.